Zevra therapeutics presents design of phase 2 clinical trial investigating kp1077 for the treatment of idiopathic hypersomnia (ih) at beyond sleepy 2023

Zevra is a corporate sponsor of the hypersomnia foundation and beyond sleepy conference celebration, fla., june 03, 2023 (globe newswire) -- zevra therapeutics, inc. (nasdaqgs: zvra) (zevra, or the company, formerly zevra.
ZVRA Ratings Summary
ZVRA Quant Ranking